Boehringer Ingelheim — Potential achievements
Products & Services · Potential achievementsEli Lilly Boehringer Ingelheim — Potential achievements decreased by 32.8% to $410.00M in Q3 2025 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2025
Last reportedQ3 2025
How to read this metric
An increase indicates successful commercialization or clinical advancement of shared assets, while a decrease may signal regulatory delays, competitive pressure, or declining market share for these specific products.
Detailed definition
This metric tracks the performance and strategic milestones associated with the partnership or product portfolio shared...
Peer comparison
Comparable to joint venture revenue, milestone payments, or royalty income reported by other pharmaceutical companies engaged in strategic R&D and commercial alliances.
Metric ID:
lly_segment_boehringer_ingelheim_potential_achievementsHistorical Data
2 periods
| Q1 '25 | Q3 '25 | |
|---|---|---|
| Value | $610.00M | $410.00M |
| QoQ Change | — | -32.8% |
Range$410.00M – $610.00M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's boehringer ingelheim — potential achievements?
- Eli Lilly (LLY) reported boehringer ingelheim — potential achievements of $410.00M in Q3 2025.
- What does boehringer ingelheim — potential achievements mean?
- This metric measures the financial and operational success of products or programs developed in partnership with Boehringer Ingelheim.